Senator Hatch and Terry
Terry & Marilu Henner
Dr. Gray & Terry
Terry receives Vity Award
Buddy and Bella
Buddy and Bella
Buddy and Bella
Terry on Tour
Terry on Tour
Terry on Tour
Terry at Marlene's - Federal Way
Soho, FL - 12/2011
Science Corner
Alpha-Lipoic Acid Supplementation in Patients with Renal Disease
In a study involving hemodialysis patients, ALA supplementation significantly reduced inflammation markers, a risk factor for cardiovascular disease. Researchers in Iran examined the effects of alpha-lipoic acid (ALA) supplementation on inflammation, oxidative stress, and serum lipid profile levels in HD patients. This double-blinded, randomized, placebo-controlled clinical trial included 63 patients with end-stage renal disease (43 men and 20 women; age range: 22-79 years) undergoing maintenance HD. Patients were randomly assigned into either the supplemented group (n = 31), receiving a daily dose of ALA (600 mg), or a control group (n = 32), receiving placebo for 8 weeks. Researchers looked at high sensitivity C-reactive protein (hsCRP), malondialdehyde, total antioxidant status, total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured at baseline and after 8 weeks of supplementation. Resu lts found that ALA supplementation was associated with a significant reduction in inflammatory markers, suggesting that ALA supplementation may reduce the risk of cardiovascular disease in hemodialysis patients.
Click here to visit the journal website. Subscription required to view the full text of the article.
Thanks for taking the time to write this post. It’s been rather helpful. It couldn’t have come at a greater time for me! http://www.ctctradeshows.com